HCSGD entry for GSK3B
1. General information
| Official gene symbol | GSK3B |
|---|---|
| Entrez ID | 2932 |
| Gene full name | glycogen synthase kinase 3 beta |
| Other gene symbols | |
| Links to Entrez Gene | Links to Entrez Gene |
2. Neighbors in the network
3. Gene ontology annotation
GO ID | GO term | Evidence | Category |
|---|---|---|---|
| GO:0000320 | Re-entry into mitotic cell cycle | IEA | biological_process |
| GO:0001085 | RNA polymerase II transcription factor binding | IPI | molecular_function |
| GO:0001837 | Epithelial to mesenchymal transition | IMP | biological_process |
| GO:0001954 | Positive regulation of cell-matrix adhesion | IMP | biological_process |
| GO:0002039 | P53 binding | IDA | molecular_function |
| GO:0004674 | Protein serine/threonine kinase activity | IDA ISS | molecular_function |
| GO:0005178 | Integrin binding | IEA | molecular_function |
| GO:0005515 | Protein binding | IPI | molecular_function |
| GO:0005524 | ATP binding | IEA | molecular_function |
| GO:0005634 | Nucleus | IDA | cellular_component |
| GO:0005730 | Nucleolus | IDA | cellular_component |
| GO:0005737 | Cytoplasm | IDA | cellular_component |
| GO:0005813 | Centrosome | IDA | cellular_component |
| GO:0005829 | Cytosol | TAS | cellular_component |
| GO:0005886 | Plasma membrane | IDA | cellular_component |
| GO:0005977 | Glycogen metabolic process | IDA | biological_process |
| GO:0006349 | Regulation of gene expression by genetic imprinting | IEA | biological_process |
| GO:0006468 | Protein phosphorylation | IDA | biological_process |
| GO:0006611 | Protein export from nucleus | IEA | biological_process |
| GO:0006983 | ER overload response | IDA | biological_process |
| GO:0007173 | Epidermal growth factor receptor signaling pathway | TAS | biological_process |
| GO:0007411 | Axon guidance | TAS | biological_process |
| GO:0007520 | Myoblast fusion | IEA | biological_process |
| GO:0007623 | Circadian rhythm | ISS | biological_process |
| GO:0008013 | Beta-catenin binding | IPI | molecular_function |
| GO:0008543 | Fibroblast growth factor receptor signaling pathway | TAS | biological_process |
| GO:0009887 | Organ morphogenesis | IEA | biological_process |
| GO:0010226 | Response to lithium ion | IEA | biological_process |
| GO:0010614 | Negative regulation of cardiac muscle hypertrophy | IEA | biological_process |
| GO:0010800 | Positive regulation of peptidyl-threonine phosphorylation | IEA | biological_process |
| GO:0016301 | Kinase activity | IDA TAS | molecular_function |
| GO:0016477 | Cell migration | IEA | biological_process |
| GO:0018105 | Peptidyl-serine phosphorylation | IDA | biological_process |
| GO:0019901 | Protein kinase binding | IPI | molecular_function |
| GO:0021766 | Hippocampus development | IMP | biological_process |
| GO:0030010 | Establishment of cell polarity | IEA | biological_process |
| GO:0030426 | Growth cone | IEA | cellular_component |
| GO:0030529 | Ribonucleoprotein complex | IEA | cellular_component |
| GO:0030877 | Beta-catenin destruction complex | IDA TAS | cellular_component |
| GO:0031333 | Negative regulation of protein complex assembly | IMP | biological_process |
| GO:0031334 | Positive regulation of protein complex assembly | IDA | biological_process |
| GO:0031625 | Ubiquitin protein ligase binding | IPI | molecular_function |
| GO:0032091 | Negative regulation of protein binding | IDA | biological_process |
| GO:0032092 | Positive regulation of protein binding | ISS | biological_process |
| GO:0032855 | Positive regulation of Rac GTPase activity | IMP | biological_process |
| GO:0032886 | Regulation of microtubule-based process | IMP | biological_process |
| GO:0033138 | Positive regulation of peptidyl-serine phosphorylation | IEA | biological_process |
| GO:0034236 | Protein kinase A catalytic subunit binding | IPI | molecular_function |
| GO:0035255 | Ionotropic glutamate receptor binding | IEA | molecular_function |
| GO:0035372 | Protein localization to microtubule | IEA | biological_process |
| GO:0035556 | Intracellular signal transduction | IDA | biological_process |
| GO:0036016 | Cellular response to interleukin-3 | ISS | biological_process |
| GO:0038095 | Fc-epsilon receptor signaling pathway | TAS | biological_process |
| GO:0042493 | Response to drug | IEA | biological_process |
| GO:0043025 | Neuronal cell body | IEA | cellular_component |
| GO:0043066 | Negative regulation of apoptotic process | IDA | biological_process |
| GO:0043197 | Dendritic spine | IEA | cellular_component |
| GO:0043198 | Dendritic shaft | IEA | cellular_component |
| GO:0043407 | Negative regulation of MAP kinase activity | IEA | biological_process |
| GO:0044027 | Hypermethylation of CpG island | IEA | biological_process |
| GO:0044337 | Canonical Wnt signaling pathway involved in positive regulation of apoptotic process | IEA | biological_process |
| GO:0045087 | Innate immune response | TAS | biological_process |
| GO:0045121 | Membrane raft | IEA | cellular_component |
| GO:0045444 | Fat cell differentiation | IEA | biological_process |
| GO:0045719 | Negative regulation of glycogen biosynthetic process | TAS | biological_process |
| GO:0045732 | Positive regulation of protein catabolic process | IC | biological_process |
| GO:0045944 | Positive regulation of transcription from RNA polymerase II promoter | IEA | biological_process |
| GO:0046827 | Positive regulation of protein export from nucleus | IDA | biological_process |
| GO:0048011 | Neurotrophin TRK receptor signaling pathway | TAS | biological_process |
| GO:0048015 | Phosphatidylinositol-mediated signaling | TAS | biological_process |
| GO:0048156 | Tau protein binding | IEA | molecular_function |
| GO:0048168 | Regulation of neuronal synaptic plasticity | IEA | biological_process |
| GO:0048471 | Perinuclear region of cytoplasm | IEA | cellular_component |
| GO:0050321 | Tau-protein kinase activity | IDA | molecular_function |
| GO:0050774 | Negative regulation of dendrite morphogenesis | IEA | biological_process |
| GO:0051059 | NF-kappaB binding | IPI | molecular_function |
| GO:0051534 | Negative regulation of NFAT protein import into nucleus | IMP | biological_process |
| GO:0060070 | Canonical Wnt signaling pathway | IC IDA | biological_process |
| GO:0071109 | Superior temporal gyrus development | IMP | biological_process |
| GO:0071260 | Cellular response to mechanical stimulus | IEA | biological_process |
| GO:0090090 | Negative regulation of canonical Wnt signaling pathway | TAS | biological_process |
| GO:0097192 | Extrinsic apoptotic signaling pathway in absence of ligand | ISS | biological_process |
| GO:1901030 | Positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | ISS | biological_process |
| GO:2000077 | Negative regulation of type B pancreatic cell development | TAS | biological_process |
| GO:2000466 | Negative regulation of glycogen (starch) synthase activity | TAS | biological_process |
| GO:2000738 | Positive regulation of stem cell differentiation | IEA | biological_process |
Entries Per Page
Displaying Page of
4. Expression levels in datasets
- Meta-analysis result
| p-value up | p-value down | FDR up | FDR down |
|---|---|---|---|
| 0.0315815129 | 0.9836591429 | 0.4109113636 | 1.0000000000 |
- Individual experiment result
( "-" represent NA in the specific microarray platform )
( "-" represent NA in the specific microarray platform )
| Data source | Up or down | Log fold change |
|---|---|---|
| GSE11954 | Up | 0.0171983262 |
| GSE13712_SHEAR | Up | 0.1255254925 |
| GSE13712_STATIC | Up | 0.1455064187 |
| GSE19018 | Up | 0.2444524070 |
| GSE19899_A1 | Up | 0.1442304848 |
| GSE19899_A2 | Up | 0.4290769755 |
| PubMed_21979375_A1 | Up | 0.1864588604 |
| PubMed_21979375_A2 | Up | 0.8378123210 |
| GSE35957 | Up | 0.5662157809 |
| GSE36640 | Up | 0.4689467890 |
| GSE54402 | Up | 0.1668420366 |
| GSE9593 | Up | 0.4537316856 |
| GSE43922 | Up | 0.1455257284 |
| GSE24585 | Up | 0.2680786428 |
| GSE37065 | Up | 0.1217429353 |
| GSE28863_A1 | Up | 0.2054935994 |
| GSE28863_A2 | Up | 0.5567163209 |
| GSE28863_A3 | Down | -0.2936647229 |
| GSE28863_A4 | Down | -0.3110783876 |
| GSE48662 | Down | -0.0479653575 |
5. Regulation relationships with compounds/drugs/microRNAs
- Compounds
Entries Per Page
Displaying Page of
- Drugs
Name | Drug | Accession number |
|---|---|---|
| Lithium | DB01356 | - |
| 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione | DB01772 | EXPT01170 |
| I-5 | DB01793 | EXPT00277 |
| N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea | DB01950 | EXPT03075 |
| Staurosporine | DB02010 | EXPT02970 | EXPT02972 |
| Indirubin-3'-Monoxime | DB02052 | EXPT01949 |
| (3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime | DB03444 | EXPT00759 |
| Alsterpaullone | DB04014 | EXPT00590 |
| Phosphoaminophosphonic Acid-Adenylate Ester | DB04395 | EXPT00524 |
| 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole | DB07014 | - |
| 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione | DB07058 | - |
| (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one | DB07149 | - |
| N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | DB07584 | - |
| 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine | DB07585 | - |
| 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one | DB07676 | - |
| N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide | DB07812 | - |
| 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE | DB07859 | - |
| ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE | DB07947 | - |
| (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE | DB08073 | - |
- MicroRNAs
- mirTarBase
MiRNA_name | mirBase ID | miRTarBase ID | Experiment | Support type | References (Pubmed ID) |
|---|---|---|---|---|---|
| hsa-miR-26a-5p | MIMAT0000082 | MIRT004676 | Luciferase reporter assay//Microarray//qRT-PCR//Western blot | Functional MTI | 20525681 |
| hsa-miR-155-5p | MIMAT0000646 | MIRT021044 | Proteomics | Functional MTI (Weak) | 19289835 |
| hsa-miR-877-3p | MIMAT0004950 | MIRT036842 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-425-5p | MIMAT0003393 | MIRT039319 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-92a-3p | MIMAT0000092 | MIRT049345 | CLASH | Functional MTI (Weak) | 23622248 |
Entries Per Page
Displaying Page of
- mirRecord
No target information from mirRecord
6. Text-mining results about the gene
Gene occurances in abstracts of cellular senescence-associated articles: 16 abstracts the gene occurs.
PubMed ID of the article | Sentenece the gene occurs |
|---|---|
| 27294914 | In addition, ginsenoside Rg1 decreased beta-catenin and c-Myc mRNA expression and enhanced the phosphorylation of GSK-3beta |
| 26683595 | Following inhibition of ASPH activity, phosphorylation of glycogen synthase kinase 3beta and p16 expression were increased to promote senescence, whereas cyclin D1 and proliferating cell nuclear antigen were decreased to reduce cell proliferation |
| 26618897 | Here we evaluated the extent of GSK3beta inactivation in vivo in OA knee cartilage and the molecular events downstream GSK3beta inactivation in vitro to assess their contribution to cell senescence and hypertrophy |
| 26618897 | METHODS: In vivo level of phosphorylated GSK3beta was analyzed in cartilage and oxidative damage was assessed by 8-oxo-deoxyguanosine staining |
| 26618897 | RESULTS: In vivo chondrocytes from obese OA patients showed higher levels of phosphorylated GSK3beta, oxidative damage and expression of GADD45beta and p21, in comparison with chondrocytes of nonobese OA patients |
| 26618897 | LiCl mediated GSK3beta inactivation in vitro resulted in increased mitochondrial ROS production, responsible for reduced cell proliferation, S phase transient arrest, and increase in cell senescence, size and granularity |
| 26618897 | CONCLUSIONS: In articular chondrocytes, GSK3beta activity is required for the maintenance of proliferative potential and phenotype |
| 26618897 | Conversely, GSK3beta inactivation, although preserving chondrocyte survival, results in functional impairment via induction of hypertrophy and senescence |
| 26618897 | Indeed, GSK3beta inactivation is responsible for ROS production, triggering oxidative stress and DNA damage response |
| 26474698 | The rats were fed with high-fat diet for 8 weeks to establish a hyperlipidemic model, which showed an increase in plasma lipids, endothelium-derived MPO expression, endothelial senescence and endothelial dysfunction concomitant with a reduction in glycogen synthase kinase 3 beta (GSK-3beta) activity and phosphorylated beta-catenin (p-beta-catenin) level as well as an increase in beta-catenin and p53 levels within the endothelium |
| 26474698 | Consistent with the finding in vivo, ox-LDL-induced MPO expression and HUVECs senescence, accompanied by a decrease in GSK-3beta activity and p-beta-catenin level as well as an increase in HOCl content, beta-catenin and p53 levels; these phenomena were attenuated by MPO inhibitor |
| 26456654 | In early passage MSCs expressing SIRT1, resveratrol decreased ERK and GSK-3beta phosphorylation, suppressing beta-catenin activity |
| 26456654 | In contrast, in late passage MSCs, which did not express SIRT1, resveratrol increased ERK and GSK-3beta phosphorylation, activating beta-catenin |
| 25777063 | The molecular mechanisms involve substrate competition of tau and beta-catenin for glycogen synthase kinase 3beta (GSK-3beta); activation of Akt; preservation of Bcl-2 and suppression of Bax, cytosolic cytochrome-c, and caspase-3 activity; and upregulation of unfolded protein response (UPR), i |
| 25437011 | Activation of the Wnt pathway by treatment with Wnt3a-conditioned medium or glycogen synthase kinase 3beta inhibitors, such as SB-216763 and 6-bromoindirubin-3'-oxime, delays the progression of cellular senescence as shown by the decrease in the senescence effectors p53 and pRb, lowered senescence-associated beta-galactosidase activity, and increased telomerase activity |
| 24296714 | Glycogen synthase kinase-3beta (GSK3beta) activity is increased in DM, potentially exacerbating impaired cell-based therapies |
| 24296714 | Thus, we aimed to determine if and how GSK3beta inhibitors (GSKi) can improve therapeutic efficacy of endothelial progenitor cells (EPC) from patients with DM |
| 24296714 | DM EPCs also exhibited higher levels of GSK3beta activity resulting in increased levels of phosphorylated beta-catenin |
| 24296714 | In DM, increased basal GSK3beta activity contributes to accelerated EPC cellular senescence, an effect reversed by small molecule antagonism of GSK3beta, which enhanced cell-based therapy after vascular injury |
| 24073285 | Moreover, our finding that reduction of glycogen synthase kinase 3 beta (GSK3beta) activity upon LiCl pretreatment inhibited both the MtNeST and production of MAP2-positive cells upon DAB2IP knockdown suggests that this transition is most likely mediated by regulation of the GSK3beta signaling pathway |
| 21678465 | Effects of a glycogen synthase kinase-3beta inhibitor (LiCl) on c-myc protein in intervertebral disc cells |
| 21418510 | Data also implied that this effect was associated with altered actions of FoxO3 and GSK-3beta |
| 19925395 | An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta |
| 19925395 | GSK3beta has well characterized roles in the regulation of gene transcription and in oncogenic signaling |
| 19925395 | This has led us to propose GSK3beta as a potential therapeutic target in cancer |
| 19925395 | Investigation of the mechanisms responsible for deregulation of GSK3beta and the consequent downstream pathologic effects in cancer cells has shed light on the molecular pathways leading to tumorigenesis |
| 19925395 | This will allow exploration of novel therapeutic strategies for cancer that target aberrant GSK3beta |
| 19407340 | We have previously shown that lithium, an inhibitor of glycogen synthase kinase (GSK)-3beta and activator of the Wnt/beta-catenin signaling pathway, induces an EC senescent-like phenotype |
| 19407340 | Lithium effect on MMP-1 expression is also specific among other MMPs and not mediated by GSK3beta inhibition |
| 18582478 | As expected, GSK-3 inhibition led to an increase of phosphorylated GSK-3beta (Ser9) and to beta-catenin accumulation |
| 15379854 | Compared with young and middle-aged human WI-38 fibroblasts, senescent cells were found to contain increased nuclear levels of GSK3beta, and also tended to accumulate in the nucleus the other isoform of GSK3, GSK3alpha |
| 15379854 | Co-immunoprecipitation experiments demonstrated that GSK3beta and p53 formed a complex in the nucleus |
| 15379854 | These results indicate that a portion of the p53 that is activated in senescent cells is modulated by its association with GSK3beta in the nucleus, an association that is known to facilitate the actions of p53 and that may contribute to senescence |
| 10982848 | We further demonstrate that in turn, the redox-dependent activation of JNK1 feeds back and inhibits the activity of the metabolic enzymes glycogen synthase kinase 3beta and glycogen synthase |
Entries Per Page
Displaying Page of
